| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | 0.0078 | 0.9 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.0079 | 0.9 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |